Reference
1. Adamski Ł J, Starzyńska A. High
PD-L1 Expression on Tumor Cells Indicates Worse Overall Survival in
Advanced Oral Squamous Cell Carcinomas of the Tongue and the Floor of
the Mouth but Not in Other Oral Compartments. Biomedicines . Sep 1
2021;9(9)doi:10.3390/biomedicines9091132
2. Cho YA, Yoon HJ, Lee JI, Hong SP,
Hong SD. Relationship between the expressions of PD-L1 and
tumor-infiltrating lymphocytes in oral squamous cell carcinoma.Oral oncology . Dec 2011;47(12):1148-53.
doi:10.1016/j.oraloncology.2011.08.007
3. Geum DH, Hwang DS. PD-L1 Expression
Correlated with Clinicopathological Factors and Akt/Stat3 Pathway in
Oral SCC. Life (Basel, Switzerland) . Feb 4
2022;12(2)doi:10.3390/life12020238
4. Lin YM, Sung WW, Hsieh MJ, et al.
High PD-L1 Expression Correlates with Metastasis and Poor Prognosis in
Oral Squamous Cell Carcinoma. PloS one . 2015;10(11):e0142656.
doi:10.1371/journal.pone.0142656
5. Ahn H, Yang JM, Kim H, et al.
Clinicopathologic implications of the miR-197/PD-L1 axis in oral
squamous cell carcinoma. Oncotarget . Sep 12
2017;8(39):66178-66194. doi:10.18632/oncotarget.19842
6. Kogashiwa Y, Yasuda M, Sakurai H,
et al. PD-L1 Expression Confers Better Prognosis in Locally Advanced
Oral Squamous Cell Carcinoma. Anticancer research . Mar
2017;37(3):1417-1424. doi:10.21873/anticanres.11465
7. Lenouvel D, González-Moles M.
Clinicopathological and prognostic significance of PD-L1 in oral cancer:
A preliminary retrospective immunohistochemistry study. Oral
diseases . Mar 2021;27(2):173-182. doi:10.1111/odi.13509
8. Satgunaseelan L, Gupta R, Madore J,
et al. Programmed cell death-ligand 1 expression in oral squamous cell
carcinoma is associated with an inflammatory phenotype.Pathology . Oct 2016;48(6):574-80.
doi:10.1016/j.pathol.2016.07.003
9. Miranda-Galvis M, Rumayor Piña A,
Sales de Sá R, et al. PD-L1 expression patterns in oral cancer as an
integrated approach for further prognostic classification. Oral
diseases . Oct 2021;27(7):1699-1710. doi:10.1111/odi.13714
10. Ukpo OC, Thorstad WL, Lewis JS,
Jr. B7-H1 expression model for immune evasion in human
papillomavirus-related oropharyngeal squamous cell carcinoma. Head
and neck pathology . Jun 2013;7(2):113-21. doi:10.1007/s12105-012-0406-z
11. Peña-Cardelles JF,
Pozo-Kreilinger JJ, Roncador G, Esteban-Hernández J, Moro-Rodríguez JE,
Sastre-Perona A. Prognosis Value of Immunoregulatory Molecules in Oral
Cancer Microenvironment: An Immunohistochemical Study.Biomedicines . Mar 19 2022;10(3)doi:10.3390/biomedicines10030710
12. de Vicente JC,
Rodríguez-Santamarta T, Rodrigo JP. PD-L1 Expression in Tumor Cells Is
an Independent Unfavorable Prognostic Factor in Oral Squamous Cell
Carcinoma. Mar 2019;28(3):546-554. doi:10.1158/1055-9965.epi-18-0779
13. McShane LM, Altman DG, Sauerbrei
W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor
marker prognostic studies (REMARK). Journal of the National Cancer
Institute . Aug 17 2005;97(16):1180-4. doi:10.1093/jnci/dji237
14. Tierney JF, Stewart LA, Ghersi D,
Burdett S, Sydes MR. Practical methods for incorporating summary
time-to-event data into meta-analysis. Trials . Jun 7 2007;8:16.
doi:10.1186/1745-6215-8-16
15. Higgins JP, Thompson SG.
Quantifying heterogeneity in a meta-analysis. Statistics in
medicine . Jun 15 2002;21(11):1539-58. doi:10.1002/sim.1186
16. Egger M, Davey Smith G, Schneider
M, Minder C. Bias in meta-analysis detected by a simple, graphical test.BMJ (Clinical research ed) . Sep 13 1997;315(7109):629-34.
doi:10.1136/bmj.315.7109.629
17. Yoshida S, Nagatsuka H, Nakano K,
et al. Significance of PD-L1 Expression in Tongue Cancer Development.International journal of medical sciences . 2018;15(14):1723-1730.
doi:10.7150/ijms.27860
18. Hirai M, Kitahara H, Kobayashi Y,
et al. Regulation of PD-L1 expression in a high-grade invasive human
oral squamous cell carcinoma microenvironment. International
journal of oncology . Jan 2017;50(1):41-48. doi:10.3892/ijo.2016.3785
19. Troeltzsch M, Woodlock T, Pianka
A, et al. Is There Evidence for the Presence and Relevance of the
PD-1/PD-L1 Pathway in Oral Squamous Cell Carcinoma? Hints From an
Immunohistochemical Study. Journal of oral and maxillofacial
surgery : official journal of the American Association of Oral and
Maxillofacial Surgeons . May 2017;75(5):969-977.
doi:10.1016/j.joms.2016.11.006
20. Quan H, Shan Z, Liu Z, et al. The
repertoire of tumor-infiltrating lymphocytes within the microenvironment
of oral squamous cell carcinoma reveals immune dysfunction. Cancer
immunology, immunotherapy : CII . Mar 2020;69(3):465-476.
doi:10.1007/s00262-020-02479-x
21. Togo M, Yokobori T, Shimizu K, et
al. Diagnostic value of (18)F-FDG-PET to predict the tumour immune
status defined by tumoural PD-L1 and CD8(+)tumour-infiltrating
lymphocytes in oral squamous cell carcinoma. British journal of
cancer . May 2020;122(11):1686-1694. doi:10.1038/s41416-020-0820-z
22. Wirsing AM, Ervik IK, Seppola M,
Uhlin-Hansen L, Steigen SE, Hadler-Olsen E. Presence of high-endothelial
venules correlates with a favorable immune microenvironment in oral
squamous cell carcinoma. Modern pathology : an official journal of
the United States and Canadian Academy of Pathology, Inc . Jun
2018;31(6):910-922. doi:10.1038/s41379-018-0019-5
23. Tojyo I, Shintani Y, Nakanishi T,
et al. PD-L1 expression correlated with p53 expression in oral squamous
cell carcinoma. Maxillofacial plastic and reconstructive surgery .
Dec 2019;41(1):56. doi:10.1186/s40902-019-0239-8
24. Akisada N, Nishimoto K, Takao S,
et al. PD-L1 expression in tongue squamous cell carcinoma. Medical
molecular morphology . Mar 2021;54(1):52-59.
doi:10.1007/s00795-020-00261-7
25. Kikuchi M, Yamashita D, Hara S,
et al. Clinical significance of tumor-associated immune cells in
patients with oral squamous cell carcinoma. Head & neck . Feb
2021;43(2):534-543. doi:10.1002/hed.26498
26. Wang H, Mao L, Zhang T, et al.
Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during
nimotuzumab therapy correlates with responses and prognosis of oral
squamous cell carcinoma patients. Journal of oral pathology &
medicine : official publication of the International Association of Oral
Pathologists and the American Academy of Oral Pathology . Sep
2019;48(8):669-676. doi:10.1111/jop.12883
27. Kouketsu A, Sato I, Oikawa M, et
al. Expression of immunoregulatory molecules PD-L1 and PD-1 in oral
cancer and precancerous lesions: A cohort study of Japanese patients.Journal of cranio-maxillo-facial surgery : official publication of
the European Association for Cranio-Maxillo-Facial Surgery . Jan
2019;47(1):33-40. doi:10.1016/j.jcms.2017.04.013
28. Straub M, Drecoll E, Pfarr N, et
al. CD274/PD-L1 gene amplification and PD-L1 protein expression are
common events in squamous cell carcinoma of the oral cavity.Oncotarget . Mar 15 2016;7(11):12024-34.
doi:10.18632/oncotarget.7593
29. Chen TC, Wu CT, Wang CP, et al.
Associations among pretreatment tumor necrosis and the expression of
HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the
prognostic impact thereof. Oral oncology . Nov
2015;51(11):1004-1010. doi:10.1016/j.oraloncology.2015.08.011
30. Takamaru N, Fukuda N, Akita K,
Kudoh K, Miyamoto Y. Association of PD-L1 and ZEB-1 expression patterns
with clinicopathological characteristics and prognosis in oral squamous
cell carcinoma. Oncology letters . Mar 2022;23(3):75.
doi:10.3892/ol.2022.13195
31. Klein M, Wermker K, Hallermann C,
Pannier F, Hölzle F, Modabber A. Immune checkpoint analysis in lip
cancer. Journal of cranio-maxillo-facial surgery : official
publication of the European Association for Cranio-Maxillo-Facial
Surgery . Oct 2021;49(10):950-958. doi:10.1016/j.jcms.2021.05.007
32. Takahashi H, Sakakura K, Arisaka
Y, et al. Clinical and Biological Significance of PD-L1 Expression
Within the Tumor Microenvironment of Oral Squamous Cell Carcinoma.Anticancer research . Jun 2019;39(6):3039-3046.
doi:10.21873/anticanres.13437
33. Sales de Sá R, Miranda Galvis M,
Mariz B, et al. Increased Tumor Immune Microenvironment CD3+ and CD20+
Lymphocytes Predict a Better Prognosis in Oral Tongue Squamous Cell
Carcinoma. Frontiers in cell and developmental biology .
2020;8:622161. doi:10.3389/fcell.2020.622161
34. Wilms T, Gu X. PD-L1 in squamous
cell carcinoma of the oral tongue shows gender-specific association with
prognosis. Oral diseases . Oct 2020;26(7):1414-1423.
doi:10.1111/odi.13414
35. Huang W, Zhou X, Liao Q, et al.
Clinicopathological and prognostic significance of PD-1/PD-L1 axis
expression in patients with tongue squamous cell carcinoma.Journal of cellular physiology . Oct 2020;235(10):6942-6953.
doi:10.1002/jcp.29590
36. Hanna GJ, Woo SB, Li YY, Barletta
JA, Hammerman PS, Lorch JH. Tumor PD-L1 expression is associated with
improved survival and lower recurrence risk in young women with oral
cavity squamous cell carcinoma. International journal of oral and
maxillofacial surgery . May 2018;47(5):568-577.
doi:10.1016/j.ijom.2017.09.006
37. Maruse Y, Kawano S, Jinno T, et
al. Significant association of increased PD-L1 and PD-1 expression with
nodal metastasis and a poor prognosis in oral squamous cell carcinoma.International journal of oral and maxillofacial surgery . Jul
2018;47(7):836-845. doi:10.1016/j.ijom.2018.01.004
38. Balermpas P, Rödel F, Krause M,
et al. The PD-1/PD-L1 axis and human papilloma virus in patients with
head and neck cancer after adjuvant chemoradiotherapy: A multicentre
study of the German Cancer Consortium Radiation Oncology Group
(DKTK-ROG). Int J Cancer . Aug 1 2017;141(3):594-603.
doi:10.1002/ijc.30770
39. Foy JP, Bertolus C, Michallet MC,
et al. The immune microenvironment of HPV-negative oral squamous cell
carcinoma from never-smokers and never-drinkers patients suggests higher
clinical benefit of IDO1 and PD1/PD-L1 blockade. Annals of
oncology : official journal of the European Society for Medical
Oncology . Aug 1 2017;28(8):1934-1941. doi:10.1093/annonc/mdx210
40. Mattox AK, Lee J, Westra WH, et
al. PD-1 Expression in Head and Neck Squamous Cell Carcinomas Derives
Primarily from Functionally Anergic CD4(+) TILs in the Presence of
PD-L1(+) TAMs. Cancer research . Nov 15 2017;77(22):6365-6374.
doi:10.1158/0008-5472.can-16-3453
41. Moratin J, Metzger K, Safaltin A,
et al. Upregulation of PD-L1 and PD-L2 in neck node metastases of head
and neck squamous cell carcinoma. Head & neck . Aug
2019;41(8):2484-2491. doi:10.1002/hed.25713
42. Naruse T, Yanamoto S, Okuyama K,
et al. Immunohistochemical Study of PD-1/PD-L1 Axis Expression in Oral
Tongue Squamous Cell Carcinomas: Effect of Neoadjuvant Chemotherapy on
Local Recurrence. Pathology oncology research : POR . Apr
2020;26(2):735-742. doi:10.1007/s12253-019-00606-3
43. Oliveira-Costa JP, de Carvalho
AF, da Silveira da GG, et al. Gene expression patterns through oral
squamous cell carcinoma development: PD-L1 expression in primary tumor
and circulating tumor cells. Oncotarget . Aug 28
2015;6(25):20902-20. doi:10.18632/oncotarget.3939
44. Schneider S, Kadletz L,
Wiebringhaus R, et al. PD-1 and PD-L1 expression in HNSCC primary cancer
and related lymph node metastasis - impact on clinical outcome.Histopathology . Oct 2018;73(4):573-584. doi:10.1111/his.13646
45. Tsai MS, Chen WC, Lu CH, Chen MF.
The prognosis of head and neck squamous cell carcinoma related to
immunosuppressive tumor microenvironment regulated by IL-6 signaling.Oral oncology . Apr 2019;91:47-55.
doi:10.1016/j.oraloncology.2019.02.027
46. Udeabor SE, Adisa AO, Orlowska A,
Sader RA, S G. Assessment of Programmed Cell Death Proteins in Oral
Squamous Cell Carcinoma. Afr J Biomed Res 2018;21:11-13.
47. Manikhas GM, Kutukova SI, Beliak
NP, Ivaskova JV, Popova NV ea. Has the PDL1 expression in tumor and
immune cells the prognostic role in oral cavity squamous cell carcinoma?J Clin Oncol 2018;36: e18025–e18025.
48. Ahmadi N, Gao K, Chia N, et al.
Association of PD-L1 expression in oral squamous cell carcinoma with
smoking, sex, and p53 expression. Oral surgery, oral medicine,
oral pathology and oral radiology . Dec 2019;128(6):631-638.
doi:10.1016/j.oooo.2019.07.008
49. Subramaniam N, Nambiar A, Dhar S,
et al. Low PDL1 Expression in Tumour Infiltrating Lymphocytes Predicts
Local Recurrence in Oral Squamous Cell Carcinoma. Indian journal
of surgical oncology . Jun 2021;12(2):408-414.
doi:10.1007/s13193-021-01333-5
50. Chen XJ, Tan YQ, Zhang N, He MJ,
Zhou G. Expression of programmed cell death-ligand 1 in oral squamous
cell carcinoma and oral leukoplakia is associated with disease progress
and CD8+ tumor-infiltrating lymphocytes. Pathology, research and
practice . Jun 2019;215(6):152418. doi:10.1016/j.prp.2019.04.010
51. Zhao L, Li P, Zhao L, et al.
Expression and clinical value of PD-L1 which is regulated by BRD4 in
tongue squamous cell carcinoma. Journal of cellular biochemistry .
Feb 2020;121(2):1855-1869. doi:10.1002/jcb.29420
52. Lenouvel D, González-Moles M,
Ruiz-Ávila I, Gonzalez-Ruiz L, Gonzalez-Ruiz I, Ramos-García P.
Prognostic and clinicopathological significance of PD-L1 overexpression
in oral squamous cell carcinoma: A systematic review and comprehensive
meta-analysis. Oral oncology . Jul 2020;106:104722.
doi:10.1016/j.oraloncology.2020.104722
53. Yang WF, Wong MCM, Thomson PJ, Li
KY, Su YX. The prognostic role of PD-L1 expression for survival in head
and neck squamous cell carcinoma: A systematic review and meta-analysis.Oral oncology . Nov 2018;86:81-90.
doi:10.1016/j.oraloncology.2018.09.016
54. Jia YQ, Yang B, Wen LL, Mu WX,
Wang Z, Cheng B. Prognostic value of immune checkpoint molecules in head
and neck cancer: a meta-analysis. Aging . Jan 22
2019;11(2):501-522. doi:10.18632/aging.101756
55. Tang H, Zhou X, Ye Y, Zhou Y, Wu
C, Xu Y. The different role of PD-L1 in head and neck squamous cell
carcinomas: A meta-analysis. Pathology, research and practice .
Jan 2020;216(1):152768. doi:10.1016/j.prp.2019.152768
56. Troiano G, Caponio VCA,
Zhurakivska K, et al. High PD-L1 expression in the tumour cells did not
correlate with poor prognosis of patients suffering for oral squamous
cells carcinoma: A meta-analysis of the literature. Cell
proliferation . Mar 2019;52(2):e12537. doi:10.1111/cpr.12537
57. Rimm DL, Han G, Taube JM, et al.
A Prospective, Multi-institutional, Pathologist-Based Assessment of 4
Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung
Cancer. JAMA oncology . Aug 1 2017;3(8):1051-1058.
doi:10.1001/jamaoncol.2017.0013
58. Xu H, Lin G. Assessment of
Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding
PD-L1 Expression in Non-Small Cell Lung Cancer. Sci Rep . Dec 5
2017;7(1):16956. doi:10.1038/s41598-017-17034-5
59. Rischin D HK, Greil R, et al.
Protocol-specified final analysis of the phase 3 KEYNOTE-048 trial of
pembrolizumab (pembro) as first-line therapy for recurrent/metastatic
head and neck squamous cell carcinoma (R/M HNSCC). J Clin Oncol2019;37:6000-6000.
60. Burtness B HK, Greil R, et al.
KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for
recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).Germany: European Society of Medical Oncology Munich . 2018;
61. Concha-Benavente F SR, Trivedi S,
et al. Identification of the cell-intrinsic and -extrinsic pathways
downstream of EGFR and IFNgamma that induce PD-L1 expression in head and
neck cancer. Cancer research . 2016;76:1031-1043.
62. Seiwert TY BB, Mehra R, et al.
Safety and clinical activity of pembrolizumab for treatment of recurrent
or metastatic squamous cell carcinoma of the head and neck
(KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet
Oncol . 2016;17:956-965.
63. Zhu Q, Cai MY, Weng DS, et al.
PD-L1 expression patterns in tumour cells and their association with
CD8(+) tumour infiltrating lymphocytes in clear cell renal cell
carcinoma. Journal of Cancer . 2019;10(5):1154-1161.
doi:10.7150/jca.29052
64. Ock CY, Keam B, Kim S, et al.
Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based
on PD-L1 and CD8 T-Cell Infiltration. Clinical cancer research :
an official journal of the American Association for Cancer Research .
May 1 2016;22(9):2261-70. doi:10.1158/1078-0432.ccr-15-2834
65. Teng MW, Ngiow SF, Ribas A, Smyth
MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1.Cancer research . Jun 1 2015;75(11):2139-45.
doi:10.1158/0008-5472.can-15-0255